Skip to main content

Picosecond Laser May Effectively Treat Nevi

A recent study showed a 755-nm picosecond pulse duration laser was safe and effective for treating dermal pigmentary conditions among Asian patients with darker skin types.

In the retrospective review, the researchers analyzed the records of 18 patients with nevi of Ota and 11 patients with Hori nevi and Fitzpatrick skin types III and IV at the National Skin Center in Singapore. The mean number of treatment sessions using a picosecond 755-nm laser were 2.22 for nevi of Ota and 3.82 for Hori nevi. Pre- and post-treatment photographs were assessed by 3 independent, blinded dermatologists using the Physician Global Assessment (PGA) score.
You may also like...

Dr Kim on Managing Dysplastic Nevi and Personalized Melanoma Screening
Patients With Benign Hyperpigmentation Willing To Pay For Cure
Hyperpigmentation Disorders Linked to OTC Lightening Agent Use

Among patients with nevi of Ota, the mean pre-treatment PGA score was 3.1 and the mean post-treatment score was 1.3. The average fluence used was for nevi of Ota was 2.02 J/cm. The mean pre- and post-treatment PGA scores were 2.6 and 1.1, respectively, in the Hori nevi group, and the average fluence was 2.08 j/cm.

Treatment-related adverse events included post-laser erythema (n=11 [37.9%]) and transient post-laser hypopigmentation (n=1 [3.4%]). However, no permanent hyperpigmentation and hypopigmentation were reported, the researchers said.

“The picosecond 755-nm laser is effective in the treatment of dermal pigmentary conditions in Asians with Fitzpatrick skin Types III [and] IV, with minimal risk of post-laser complications,” the researchers concluded. They also noted that the laser resulted in faster and more effective pigment clearance compared with the center’s past experience with the Q-switched nanosecond 1064-nm laser.


Koh YP, Tan AWM, Chua SH. Treatment of laser-responsive dermal pigmentary conditions in type III-IV Asian skin with a 755-nm picosecond pulse duration laser: A retrospective review of its efficacy and safety [published online February 13, 2020]. Dermatol Surg. doi:10.1097/DSS.0000000000002332

Back to Top